Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 4,372 |
|
|||||
| News | - | ||||||
| Day High | 4.0807 | Low High |
|||||
| Day Low | 3.86 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.13 | 3.36% | 4.00 | 10:03:02 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.86 | 3.86 | 4.0807 | 3.87 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 30 | 4,372 | US$ 3.89 | US$ 17,022 | - | 1.66 - 9.6799 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 10:14:20 | 3 | US$ 4.0715 | USD |
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 36M | 8.89M | - | 3.31M | -8.24M | -0.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marker Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/17/2024 | 17:25 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 5/15/2024 | 15:40 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/15/2024 | 15:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 4/08/2024 | 06:00 | GlobeNewswire Inc. | Principal Investigator from City of Hope National Medical.. |
| 3/25/2024 | 16:45 | GlobeNewswire Inc. | Marker Therapeutics Reports Year-End 2023 Corporate and.. |
| 3/22/2024 | 11:30 | GlobeNewswire Inc. | Marker Therapeutics to Present at the H.C. Wainwright 2nd.. |
| 3/01/2024 | 07:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/26/2024 | 06:58 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/22/2024 | 06:30 | GlobeNewswire Inc. | Marker Therapeutics Receives Approval from United States.. |
| 1/08/2024 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/08/2024 | 07:24 | GlobeNewswire Inc. | Marker Therapeutics Announces Clinical Program Updates and.. |
| 12/21/2023 | 10:00 | GlobeNewswire Inc. | Marker Therapeutics Announces Participation in Biotech.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.14 | 4.27 | 3.78 | 3.92 | 10,081 | -0.14 | -3.38% |
| 1 Month | 4.22 | 4.40 | 3.68 | 4.07 | 9,487 | -0.22 | -5.21% |
| 3 Months | 4.16 | 4.93 | 3.68 | 4.38 | 15,490 | -0.16 | -3.85% |
| 6 Months | 2.67 | 6.1568 | 2.67 | 4.58 | 49,249 | 1.33 | 49.81% |
| 1 Year | 1.76 | 9.6799 | 1.66 | 4.66 | 85,759 | 2.24 | 127.27% |
| 3 Years | 31.00 | 36.50 | 0.6706 | 8.18 | 492,203 | -27.00 | -87.10% |
| 5 Years | 55.70 | 91.70 | 0.6706 | 19.10 | 640,928 | -51.70 | -92.82% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |
